Return to homepagePandemic Pact

Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by coronavirus SARS-CoV-2 (COVID-19)

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00005

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Félix Gutiérrez Rodero

  • Research Location

    Spain

  • Lead Research Institution

    Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

This is a multicenter, randomized, double-blind, two-arm clinical trial comparing the efficacy and safety of mefloquine versus placebo for prophylaxis against COVID-19 in close contacts of infected people. As well as establishing whether the preventive administration of mefloquine attenuates the clinical manifestations of COVID-19 in people who become infected, while seeking to evaluate the safety of prophylactic mefloquine in this scenario. To do this, 200 contacts of people in close contact with patients infected by COVID-19 will be selected and they will be randomly assigned to one or another arm of the study and who must follow the indicated administration schedule (one tablet to week)